PepLabo Download

GLP‑1 medicines after pregnancy and while breastfeeding

After a birth, questions about weight, feeding and a future pregnancy often arrive at once. Here is what the labels themselves say about breastfeeding and pregnancy planning, so the conversation with your clinician starts from the same page.

Published · Updated · Hormones and life stages · Written by the PepLabo editorial team

What do the labels say about breastfeeding?

  • Wegovy® injection: the label says there are no data on whether injected semaglutide is in human milk, or on effects on the breastfed infant or milk production. It asks for the benefits of breastfeeding to be considered together with the mother’s clinical need for the medicine.[1]
  • Wegovy® tablets: the label says breastfeeding is not recommended during treatment, because an absorption ingredient in the tablet (SNAC) passes into milk and could build up in infants.[1]
  • Zepbound® and Mounjaro® (tirzepatide): in a single-dose study in 11 breastfeeding women, tirzepatide was undetectable in most milk samples and low in the rest. There are no data on effects on the infant or on milk production; the label again asks for the same weighing of benefits and needs.[3][4]

NIH’s LactMed database summarises published reports on semaglutide and breastfeeding and is updated as new studies appear. It is a reference for clinicians, not a personal recommendation.[5]

When should semaglutide be stopped before another pregnancy?

The Wegovy® and Ozempic® labels say to stop semaglutide at least 2 months before a planned pregnancy, because it stays in the body for a long time.[1][2] The tirzepatide labels add a note on contraception: in the first four weeks and the four weeks after every step up, the pill may work less well, so the labels point to a contraceptive that is not swallowed, or a condom alongside it, during those weeks.[3][4]

Why do fluids matter in the first months?

Sleep is short, meals are irregular and fluids matter when breastfeeding. The Wegovy® label warns that nausea, vomiting or diarrhoea can lead to dehydration and kidney problems, and asks patients to drink fluids and report persistent stomach symptoms promptly.[1] That warning is worth keeping in mind in the postpartum weeks.

What does PepLabo not do?

PepLabo is a log. It does not diagnose, measure hormones or body composition, suggest a dose or tell you when to change one.

It records what you choose to note; it does not tell you whether a medicine is compatible with breastfeeding.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S; Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. They are named only to identify the medicines and their labels. PepLabo has no affiliation with these companies.

When to get help

SignWho to contactHow fastSource
Nausea, vomiting or diarrhoea that does not go away, or signs of dehydrationYour prescriberTodayWegovy® Medication Guide[1]
You think you might be pregnant againYour prescriberTodayWegovy® label §17[1]
Swelling of face, lips, tongue or throat, trouble breathing, severe rashEmergency services — stop the medicineEmergencyWegovy® Medication Guide[1]

Questions

Can I take a GLP-1 medicine while breastfeeding?

The labels do not give a simple answer. They describe what is known — which differs between semaglutide injection, semaglutide tablets and tirzepatide — and ask you and your clinician to weigh the benefits of breastfeeding against your need for the medicine.[1][3][4]

How long before a pregnancy should semaglutide be stopped?

The Wegovy® and Ozempic® labels say at least 2 months before a planned pregnancy.[1][2] Plan the timing with your prescriber.

Set up your lab tonight.

It takes a few minutes. Pep will be waiting.